Thank you for donating!

You can donate using the following services.

Donate

NPUK relies entirely on voluntary donations and fundraising to enable us to continue our work in supporting the children, adults, and families that are affected by Niemann-Pick disease. We’ve only been able to achieve what we have thanks to the voluntary donations and fundraising efforts of people like you. However, we know we can achieve much more so please continue to support us in any way you can – your kindness will help change lives.

Your donations, whether big or small, make a difference:

How you can donate:

  • If you live in the UK you can donate to NPUK easily from your mobile phone – simply text: NPUK02 followed by the amount you’d like to donate to 70070. For example e.g. “NPUK02 £5” to 70070 (UK ONLY). These donations are handled by our Just Giving account, and go directly into our fundraising account.
  • You can also donate to our Virgin Money Giving and Just Giving accounts online.

Thank you from everyone here are NPUK!

 

Latest news

15.03.19

CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol® Cyclo™ in Alzheimer’s Disease

ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.

Read more

11.03.19

IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC)

IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC): OXFORD, UK, March 11, 2019-- IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC).

Read more
View all news Subscribe